Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Thank You. sounds good ... for now.
Thank You. Hope something comes out of MT-401 OTS.
I'm guessing that this no new nothing news means that there ain't going to be any earth shattering news given by Juan at tomorrows presentation.
YAWN!
Ho Hum, it looks like the same Old information being told again for the 10th time.
Thanks for the update on lymphoma patient #1 again, again.
MARKER THERAPEUTICS REPORTS YEAR-END 2023 CORPORATE AND FINANCIAL RESULTS
https://ir.markertherapeutics.com/news-releases/news-release-details/marker-therapeutics-reports-year-end-2023-corporate-and
Hello Phantom, asking in advance. After Juan does his March 26 presentation, can you translate it here and give your outlook? Thank You
volume 17,000 , that's not a lot of excitment.
Nice move, but the pitiful volume Sucks.
Ho Hum. go mrkr. rah rah rah.
should start tomorrow.
Lymphoma patient #2? Lymphoma patient #3? We can expect some data when?
Well, we can look at the bright side. At least we have the name "Neldaleucel" ready ... in case we ever get to use it to market ...
in 3 or 4 years if we're lucky.
GO METS you see we have out own "Acuna" now.
OK, let me get this straight.
It has been more than 20 years since TPIV came public,
about 6 years since the MRKR merger,
and what we have to show for it is basically nothing.
All TPIV legacy gone bye bye.
MRKR AML just about gone bye bye.
And here we are, back to almost square one, with a single early Phase 1 Lymphoma trial.
Just Peachy.
Marker Therapeutics, Inc. has terminated its stock sale agreement with Lincoln Park Capital Fund, effective March 1, 2024, citing sufficient financial runway until the fourth quarter of 2025, negating the immediate need for further capital.
Well, at least we were given information on the first lymphoma study participant for what, the FOURTH or FIFTH TIME now.
Thank You for the helpful update.
Do I detect a wee bit of sarcasm?
If so, I 100% agree with it.
Thank You, I guess that news is better than a sharp stick in the eye.
Now just let it lead to something meaningful and profitable.
If in March we get the FDA hold lifted ... and let's say that pushes the price past $20, which I think is more than reasonable, with just the rest of their pipeline which is using the Same therapy that is already proven and approved, that should be worth what? Somewhere between $30 and $40.
So seriously, IF BEFORE we even factor in ever increasing revenues that will be coming in, any buy out offer would have to be north of $50, perhaps well north.
4AM BLAST OFF 🚀🚀🚀💲💲💲👀💲💲💲🚀🚀🚀😵
A MRKR cancer competitor (but not much) IOVA got an early FDA approval today, good box label, (posted here 2 days ago and before).
P.S. - after almost 7 decades, you taught me something,
I never knew the word was drivel or seen it spelled out.
I always thought it was dribble. Thanks
P.P.S. I miss all them potato fields and chicken farms from our youth on L.I. (and everything that went with them),
with all of our modern technology, it seems like this world just gets worse and worse, I liked it better when neighbors and people actually cared about each other, and we were allowed to have freedom of speech and our own opinions without cancel culture.
Howdy ATL. GO MRKR - GO METS
I haven't seen any of his posts because I have barchild blocked, but I'm guessing that he is still babbling on with his assinine dribble.
MRKR just kind of hanging out here.
10 days left before IOVA date for FDA PDUFA approval.
New T cell therapy for Lymphoma ... clinical trials still a few years away.
https://www.msn.com/en-us/health/other/new-technique-could-make-human-t-cells-100-times-more-potent-at-killing-cancer-cells/ar-BB1hVKbW?ocid=msedgdhp&pc=U531&cvid=7a02c55157864e2ba3eef48328824d64&ei=17
"a gene fusion, CARD11–PIK3R3, found in a CD4 cutaneous T cell lymphoma, that augments CARD11–BCL10–MALT1 complex signalling and anti-tumour efficacy of therapeutic T cells in several immunotherapy-refractory models in an antigen-dependent manner."
https://www.nature.com/articles/s41586-024-07018-7
Good Luck to both of us.
No, it did not. I am a long term investor in this, I still have faith for much bigger things in the future.
Thank You. I hope MRKR can report some very positive news soon, with all these new treatments, we don't want to get left in the dust. We have a bit of a head start, lets take advantage of it while we still have it.
Phantom, Does the following have anything similar to do with the hypomethylating agent that MRKR was doing with MT-401?
Kobayashi and his team discovered a gene named NLRC5 that controls the levels of MHC class I. They also realized that in cancers, this gene gets suppressed when certain molecular switches on DNA are turned off.
This turning off, called DNA methylation, reduces the levels of MHC class I, helping cancer cells hide.
Their new method, TRED-I (Targeted Reactivation and Demethylation for MHC-I), can reverse the DNA methylation of the NLRC5 gene and activate it again.
Doing this increases the levels of MHC class I in cancer cells without causing serious side effects. It's like flipping a switch to make the immune system see and fight against cancer cells more effectively.
https://www.msn.com/en-us/health/other/crispr-just-made-it-easier-for-the-immune-system-to-destroy-cancer/ar-BB1hvBML?ocid=msedgdhp&pc=U531&cvid=e0b4244c642c47efb86149d7bf22b334&ei=33
Negative CAR-T information report:
The FDA has received numerous reports from doctors and researchers linking CAR T to the development of secondary cancers, specifically cancers involving T cells.
The FDA has sent letters to six makers of CAR T products telling them to include a new boxed warning detailing the possible risk in their products’ labeling.
https://www.msn.com/en-us/health/other/groundbreaking-cancer-treatment-may-actually-raise-risk-of-secondary-cancers/ar-BB1hceQt?ocid=msedgdhp&pc=U531&cvid=98b233a6100d4af3b2fdab890a8604f9&ei=48
LET'S GO MULTI-TAA.
After the recent AML news, and pretty much everything riding on Lymphoma, I think MRKR is a case of ...
hope for the best but prepare for the worst.
But I'll still click on the green bull for now.
and all we can do is hang in there, hurry up and wait ... and hope.
No, It seemed to me that MRKR took a very long time to enroll in AML but that was kind of halted because of Covid. They don't have that excuse anymore and since the Lymphoma trial is open, all I can say is, the sooner the better. I think one problem MRKR has all along for any trials is awareness. If Doctors and patiants don't know about your company or trials, it's hard to sign them up for it. I hate to say this ... but ... how much of this recuiting for trials has to do with both Hospital competition and greed. In other words if MRKR contacts M.D. Anderson or Mayo Clinic and says: "we have this therapy for patients "X", you might want to enroll them in our trial. Will those Hospitals and Doctors recommend that their patients go elsewhere for treatment because they would both no longer be able to charge the Insurance companies for any treatments that they themselves would have given and billed for?? I would hope not, but people are people.
Thank You, THAT is a very good point that I completely forgot about.
"What about the addition of the hypomethylating agent combined with MT-401? Was that non clinical test they did last year for nothing? What are they planning with it?"
I would love to have those answers.
Well, maybe if we wait another 6 or 12 months, they might get around to answering your questions instead of just telling us stuff we already knew for the fifth time.
MRKR made it into Benzinga: Well worded article - it might get MRKR some exposure and might even push the price up today and the rest of the week.
https://www.msn.com/en-us/health/other/cancer-cell-therapy-focused-marker-therapeutics-announces-pipeline-prioritization/ar-AA1mDceP?ocid=msedgdhp&pc=U531&cvid=2e5c29ccbcc047229586c06e773974b6&ei=35
It didn't sound good to me, but yet, the price is going up, really don't understand it, but I'll take it.
If people are buying because of the lymphoma "news", everything they reported today was "old" news one just one patient, nothing new that I saw.
But hey, let the price keep going up, fine by me.
Phantom: when you get a chance, can you give your opinions on:
https://ir.markertherapeutics.com/news-releases/news-release-details/marker-therapeutics-announces-clinical-program-updates-and-0
Thank You